Dr Reddy's Laboratories EBITDA 2010-2024 | RDY

Dr Reddy's Laboratories annual and quarterly EBITDA history from 2010 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Dr Reddy's Laboratories EBITDA for the quarter ending September 30, 2024 was $0.256B, a 1.99% decline year-over-year.
  • Dr Reddy's Laboratories EBITDA for the twelve months ending September 30, 2024 was $0.988B, a 5.48% increase year-over-year.
  • Dr Reddy's Laboratories 2024 annual EBITDA was $0.99B, a 16.61% increase from 2023.
  • Dr Reddy's Laboratories 2023 annual EBITDA was $0.849B, a 55.78% increase from 2022.
  • Dr Reddy's Laboratories 2022 annual EBITDA was $0.545B, a 12.66% decline from 2021.
Dr Reddy's Laboratories Annual EBITDA
(Millions of US $)
2024 $990
2023 $849
2022 $545
2021 $624
2020 $600
2019 $478
2018 $363
2017 $382
2016 $602
2015 $552
2014 $553
2013 $457
2012 $467
2011 $351
2010 $316
2009 $-4
Dr Reddy's Laboratories Quarterly EBITDA
(Millions of US $)
2024-09-30 $256
2024-06-30 $261
2024-03-31 $219
2023-12-31 $252
2023-09-30 $261
2023-06-30 $258
2023-03-31 $179
2022-12-31 $238
2022-09-30 $239
2022-06-30 $193
2022-03-31 $48
2021-12-31 $164
2021-09-30 $204
2021-06-30 $129
2021-03-31 $149
2020-12-31 $157
2020-09-30 $168
2020-06-30 $150
2020-03-31 $144
2019-12-31 $145
2019-09-30 $150
2019-06-30 $161
2019-03-31 $127
2018-12-31 $129
2018-09-30 $110
2018-06-30 $112
2018-03-31 $84
2017-12-31 $126
2017-09-30 $104
2017-06-30 $49
2017-03-31 $105
2016-12-31 $126
2016-09-30 $94
2016-06-30 $57
2016-03-31 $113
2015-12-31 $153
2015-09-30 $179
2015-06-30 $157
2015-03-31 $169
2014-12-31 $146
2014-09-30 $120
2014-06-30 $135
2014-03-31 $123
2013-12-31 $159
2013-09-30 $144
2013-06-30 $90
2013-03-31 $127
2012-12-31 $99
2012-09-30 $141
2012-06-30 $93
2012-03-31 $193
2011-12-31 $163
2011-09-30 $66
2011-06-30 $94
2011-03-31 $63
2010-12-31 $87
2010-09-30 $110
2010-06-30 $74
2010-03-31 $8
2009-12-31 $79
2009-09-30 $74
2009-06-30 $93
2009-03-31 $204
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $11.853B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.395B 6.36
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Bausch Health Cos (BHC) Canada $2.931B 2.13
Amphastar Pharmaceuticals (AMPH) United States $2.186B 13.14
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Taysha Gene Therapies (TSHA) United States $0.506B 35.29
Personalis (PSNL) United States $0.245B 0.00
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00